GlassScriptPhysician profile
Roberto Bermudez
NPI 1780781138
$8,622.99
in general payments reported to CMS, 2019-2025
40 companies · $956 in 2025
The $956 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,606 · 2020: $1,623 · 2021: $1,916 · 2022: $1,029 · 2023: $585 · 2024: $907 · 2025: $956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,448.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,730.32 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $751.26 | 2019-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $721.23 | 2019-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $463.18 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $430.09 | 2019-2022 | |
| Glaxosmithkline, LLC. | $421.27 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $362.41 | 2019-2021 | |
| Lilly USA, LLC | $308.27 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $303.60 | 2021-2025 | |
| Viiv Healthcare Company | $286.06 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $189.29 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.13 | 2020-2025 | Jardiance, Synjardy |
| Sunovion Pharmaceuticals INC. | $155.59 | 2019-2020 | |
| Esperion Therapeutics, INC. | $120.74 | 2021-2024 | Nexletol |
| Allergan, INC. | $116.38 | 2020 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Bermudez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.